Background: The incidence of tuberculosis (TB) in end-stage renal disease is significantly higher than that in the general population. Among those with kidney dysfunction, anti-TB treatment is associated with increased side effects, but the effect on healthcare utilization is unknown. Methods/Aim: To assess patient-reported symptoms, adverse effects and describe changes in healthcare utilization patterns during treatment for TB, we conducted a case series (n = 12) of patients receiving maintenance hemodialysis (HD) from Mayo Clinic Dialysis Services and concurrent drug therapy for TB from January 2002 through May 2014. Healthcare utilization (hospitalizations and emergency department (ED) visits independent of hospital admission) was compared before and during treatment. Results: Patients were treated for latent (n = 7) or active (n = 5) TB. The majority of patients with latent disease were treated with isoniazid (n = 5, 71%), while active-disease patients received a 4-drug regimen. Adverse effects were reported in 83% of patients. Compared to measurements prior to drug initiation, serum albumin and dialysis weights were similar at 3 months. Commonly reported anti-TB drug toxicities were described. More than half (58%) of the patients were hospitalized at least once. No ED or hospital admissions occurred in the period prior to drug therapy, but healthcare utilization increased during treatment in the latent disease group (hospitalization rate per person-month: pre 0 vs. post 1). Conclusions: Among HD patients, anti-TB therapy is associated with frequently reported symptoms and increased healthcare utilization. Among this subset, patients receiving treatment for latent disease may be those with greatest increase in healthcare use. Careful monitoring and early complication detection may help optimize medication adherence and minimize hospitalizations.

Keywords:
Dialysis, End-stage renal disease, Healthcare utilization, Hospitalization, Maintenance hemodialysis
1.
World Health Organization: Global Tuberculosis Report, 2014-2015.
2.
Al-Efraij K, Mota L, Lunny C, Schachter M, Cook V, Johnston J: Risk of active tuberculosis in chronic kidney disease: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2015;19:1493-1499.
3.
Segall L, Covic A: Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 2010;5:1114-1122.
4.
Unsal A, Ahbap E, Basturk T, Koc Y, Sakaci T, Sinangil Arar A, Kayabasi H, Sevinc M: Tuberculosis in dialysis patients: a nine-year retrospective analysis. J Infect Dev Ctries 2013;7:208-213.
5.
Ahmed AT, Karter AJ: Tuberculosis in California dialysis patients. Int J Tuberc Lung Dis 2004;8:341-345.
6.
Hussein MM, Mooij JM, Roujouleh H: Tuberculosis and chronic renal disease. Semin Dial 2003;16:38-44.
7.
Fang HC, Lee PT, Chen CL, Wu MJ, Chou KJ, Chung HM: Tuberculosis in patients with end-stage renal disease. Int J Tuberc Lung Dis 2004;8:92-97.
8.
Christopoulos AI, Diamantopoulos AA, Dimopoulos PA, Goumenos DS, Barbalias GA: Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial. BMC Nephrol 2009;10:36.
9.
Klote MM, Agodoa LY, Abbott KC: Risk factors for mycobacterium tuberculosis in US chronic dialysis patients. Nephrol Dial Transplant 2006;21:3287-3292.
10.
Abdelrahman M, Sinha AK, Karkar A: Tuberculosis in end-stage renal disease patients on hemodialysis. Hemodial Int 2006;10:360-364.
11.
Shu CC, Wu VC, Yang FJ, Pan SC, Lai TS, Wang JY, Wang JT, Lee LN: Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis. PLoS One 2012;7:e42592.
12.
Quantrill SJ, Woodhead MA, Bell CE, Hardy CC, Hutchison AJ, Gokal R: Side-effects of antituberculosis drug treatment in patients with chronic renal failure. Eur Respir J 2002;20:440-443.
13.
Yang WF, Han F, Zhang XH, Zhang P, Chen JH: Extra-pulmonary tuberculosis infection in the dialysis patients with end stage renal diseases: case reports and literature review. J Zhejiang Univ Sci B 2013;14:76-82.
14.
Kazancioglu R, Ozturk S, Gursu M, Avsar U, Aydin Z, Uzun S, Karadag S, Tatli E, Sar F: Tuberculosis in patients on hemodialysis in an endemic region. Hemodial Int 2010;14:505-509.
15.
Ko YC, Lee CT, Cheng YF, Hung KH, Kuo CY, Huang CC, Chen JB: Hypercalcaemia and haemophagocytic syndrome: rare concurrent presentations of disseminated tuberculosis in a dialysis patient. Int J Clin Pract 2004;58:723-725.
16.
Rao TM, Ram R, Swarnalatha G, Santhosh Pai BH, Ramesh V, Rao CS, Naidu GD, Dakshinamurty KV: Tuberculosis in haemodialysis patients: a single centre experience. Indian J Nephrol 2013;23:340-345.
17.
Getahun H, Matteelli A, Chaisson RE, Raviglione M: Latent mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-2135.
18.
Sia IG, Wieland ML: Current concepts in the management of tuberculosis. Mayo Clin Proc 2011;86:348-361.
19.
Jensen PA, Lambert LA, Iademarco MF, Ridzon R: Guidelines for preventing the transmission of mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005;54:1-141.
20.
Dobler CC, McDonald SP, Marks GB: Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One 2011;6:e29563.
21.
Horsburgh CR Jr, Rubin EJ: Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011;364:1441-1448.
22.
Centers for Disease Control and Prevention (CDC); American Thoracic Society: Update: adverse event data and revised American thoracic society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
23.
Siskind MS, Thienemann D, Kirlin L: Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature. Nephron 1993;64:303-306.
24.
Abbas MT, Khan FY, Sulimon S, Baidaa A: Encephalopathy secondary to isoniazid in patients on hemodialysis. Indian J Nephrol 2013;23:54-56.
25.
American Thoracic Society CDC, Infectious Diseases Society of America: Treatment of Tuberculosis. Morbidity and Mortality Weekly Report, 2003, vol 52, pp 1-77.
26.
Hickson LJ, Chaudhary S, Williams AW, Dillon JJ, Norby SM, Gregoire JR, Albright RC Jr, McCarthy JT, Thorsteinsdottir B, Rule AD: Predictors of outpatient kidney function recovery among patients who initiate hemodialysis in the hospital. Am J Kidney Dis 2015;65:592-602.
27.
Schoonover KL, Hickson LJ, Norby SM, Hogan MC, Chaudhary S, Albright RC Jr, Dillon JJ, McCarthy JT, Williams AW: Risk factors for hospitalization among older, incident haemodialysis patients. Nephrology (Carlton) 2013;18:712-717.
28.
Targeted tuberculin testing and treatment of latent tuberculosis infection. American thoracic society. MMWR Recomm Rep 2000;49:1-51.
29.
Rabassa AA, Trey G, Shukla U, Samo T, Anand BS: Isoniazid-induced acute pancreatitis. Ann Intern Med 1994;121:433-434.
30.
Centers for Medicare and Medicaid Services (CMS): National Dry Run Report: Standardized Readmission Ratio (SRR) for Dialysis Facilities. ESRD Quality Measure Development, Maintenance, and Support, UM-KECC, 2014.
31.
Centers for Medicare and Medicaid Services (CMS): Readmissions Reduction Program, 2015.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.